Abstract
In this article the problems of improving the control of bronchial asthma through optimization of bronchodilator therapy are discussed. Cholinergic mechanisms in the pathogenesis of asthma and the possibilities of use of long-acting m-anticholinergic - tiotropium (via liquid inhaler R espimat) - in the treatment of this disease are shown. Pharmacological properties of bronchodilators are discussed to identify the main groups of patients who need tiotropium therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
